Skip to main content
. 2020 May 27;11:962. doi: 10.3389/fimmu.2020.00962

Table 1.

Clinical studies assessing TB sequelae.

References Study site Study type and design post-treatment commencement ATB sample size, n Nature of residual lung impairment Associated inflammatory response
Ngahane et al. (46) Cameroon Cross-sectional Includes HIV+ 269 Structural (CXR lesions) and Functional (dyspnoea and spirometry) No
Ralph et al. (13) Indonesia Longitudinal [Baseline (BL), 6M & over 6M] Includes HIV+ 200 Structural (CXR score of lesions and cavitation) and Functional (dyspnoea, SGRQ, spirometry) No
Kumar et al. (47) India Longitudinal (BL & 6M) No HIV+ cases Part of larger study involving patients with co-morbidities 24 Structural (cavitation; no CXR-score) Yes
Ravimohan et al. (48) USA Prospective (over 6M) All TB/HIV+ 14 Functional (spirometry) Yes (MMPs)
Pasipanodya et al. (11) USA Longitudinal (BL, 6M & over 6M) Includes HIV+ 177 Functional (SGRQ and spirometry) No
Plit et al. (42) South Africa Longitudinal (BL & 6M) Includes HIV+ 76 Structural (CXR score of lung infiltrates) Functional (spirometry) Yes (c-reactive protein (CRP) and serum α1-protease inhibitor (α1-PI)
Cole et al. (43) South Africa Cross-sectional Includes HIV+ 55 Functional (SGRQ and spirometry) No
Patil and Patil (44) India Longitudinal (6M, 9M, & 12M) No HIV+ cases 118 Functional (dyspnoea and spirometry) No
Hnizdo et al. (4) South Africa Retrospective (BL-−375M) Includes HIV+ 2,599 Functional (spirometry) No
Maguire et al. (45) Indonesia Longitudinal (BL, 2M, & 6M) Includes HIV+ 115 Functional (dyspnoea, SGRQ, spirometry) No
Saldana et al. (41) Mexico Cross-sectional Includes HIV+ 127 Functional (Spirometry) and Structural (CXR abnormalities) No
Vecino et al. (14) USA Longitudinal (BL, 6M, & over 6M) 123 Functional (Spirometry) No
Chushkin et al. (3) Russia Prospective (Over 12M) Undetermined HIV status 214 Functional (Spirometry) No